Please type a plus sign (+) inside this box +

PTO/SB/08A (08-00)
Approved for use through 10/31/2002 OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 3

Complete if Known	
Application Number	09/760,364
Filing Date	January 12, 2001
First Named Inventor	Lehmann, Jurgen M.
Group Art Unit	1646
Examiner Name	Not yet assigned
Attorney Docket Number	018781-004110US

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	U.S. Patent Document: Number	Kind Code[2] (*if known*)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1	5,686,574	A	Moore, *et al.*	11-11-1997	
	1	5,710,017	A	Moore, *et al.*	01-20-1998	
	3	5,756,448	A	Moore, *et al.*	05-26-1998	
	4	5,902,726	A	Kliewer, *et al.*	05-11-1999	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document: Office[3]	Number[4]	Kind Code[5] (*if known*)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
	5	EP	WO 96/36230	A1		11-21-1996		☐
	6	EP	WO 99/15555	A1		04-01-1999		☐
	7	EP	WO 99/273365	A1		06-03-1999		☐
	8	EP	0608532	A2		08-03-1994		☐
								☐

Examiner Signature		Date Considered	8-12-04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] See attached Kinds of U.S. Patent Documents. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → [+]

PTO/SB/08B (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 3

Complete if Known	
Application Number	09/760,364
Filing Date	January 12, 2001
First Named Inventor	Lehmann, Jurgen M.
Group Art Unit	1646
Examiner Name	Not yet assigned
Attorney Docket Number	18781-004110

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	9	BAES, *et al.* "A New Orphan Member of the Nuclear Hormone Receptor Superfamily that Interacts with a Subset of Retinoic Acid Response Elements" *Molecular and Cellular Biology*, *14(3)*:1544-1552 (1994)	☐
	10	BLUMBERG, *et al.* "Orphan Nuclear Receptors – New Ligands and New Possibilities" *Gene & Development*, *12*:3149-3155 (1998)	☐
	11	CHOI, *et al.* "Differential Transactivation by Two Isoforms of the Orphan Nuclear Hormone Receptor CAR" *The J. of Biological Chemistry*, *272(38)*:23565-23571 (1997)	☐
	12	DE LUCA, "Reverse Endocrinology as an Approach to Drug Discovery" *Drugs of the Future*, *24(11)*:1213-1219 (1999)	☐
	13	FORMAN, *et al.* "Androstane Metabolites Bind to and Deactivate the Nuclear Receptor CAR-β" *Nature*, *395(8)*:612-615 (1998)	☐
	14	GUAN, *et al.*, "Eukarotic Proteins Expressed in *Escherichia coli: An Improved Thrombin Cleavage and Purification Procedure of Fusion Proteins with Glutathione S-Transferase" Anal. Biochem.*, *192*:262-267 (1991)	☐
	15	HONKAKOSKI, *et al.* "The Nuclear Orphan Receptor CAR-retinoid X Receptor Heterodimer Activates the Phenobarbital-Responsive Enhancer Module of the *CYP2B* gene" *Molecular and Cellular Biology*, *18(10)*:5652-5658 (1998)	☐
	16	JAENISCH, "Transgenic Animals" *Science*, *240*:1468-1474 (1988)	☐
	17	KLIEWER, *et al.* "Orphan Nuclear Receptors: Shifting Endocrinology into Reverse" *Science*, *284*:757-760 (1999)	☐
	18	KAWAMOTO, *et al.* "Phenobarbital-Responsive Nuclear Translocation of the Receptor CAR in Induction of the CYP2B Gene" *Molecular and Cellular Biology*, *19(9)*:6318-6322 (1999)	☐
	19	MAKISHIMA, *et al.* "Identification of a Nuclear Receptor for Bile Acids" *Science*, *284*:1362-1365 (1999)	☐
	20	MOORE, *et al.* "Orphan Nuclear Receptors Constitutive Androstande Receptor and Pregnane X Receptor Share Xenobiotic and Steroid Ligands" *The J. of Biological Chemistry*, *275(20)*:15122-15127 (2000)	☐
	21	PARKER, *et al.* "The Roles of Steroidogenic Factor-1 in Reproductive Function" *Steroids: Structure, Function, and Regulation*, *61(4)*:161-165 (1996)	☐

Examiner Signature		Date Considered	8/12/02

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231

WC 9031963 v1

Please type a plus sign (+) inside this box → +

PTO/SB/08B (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 3 of 3

Complete if Known	
Application Number	09/760,364
Filing Date	January 12, 2001
First Named Inventor	Lehmann, Jurgen M.
Group Art Unit	1646
Examiner Name	Not yet assigned
Attorney Docket Number	18781-004110

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	22	PARKS, *et al.* "Bile Acids: Natural Ligands for an Orphan Nuclear Receptor" *Science, 284*:1365-1368 (1999)	☐
	23	POLAND, *et al.* "1,4Bis[2-(3,5-Dichloropyridyloxy)] Benzene, a Potent Phenobarbital-like Inducer of Microsomal Monooxygenase Activity" *Mol. Pharmacol., 8*:571-580 (1980)	☐
	24	SCHINDLER, *et al.* "Components of a Stat Recognition Code: Evidence for Two Layers of Molecular Selectivity" *Immunity, 2*:689-697 (1995)	☐
	25	SMITH, *et al.*, "Single-step Purification of Polypeptides Expressed in *Escherichia Coli* as Fusion with Glutathione S-transferase" *Gene, 67*:31-40 (1988)	☐
	26	SUEYOSHI, *et al.* "The Repressed Nuclear Receptor CAR Responds to Phenobarbital in Activating the Human *CYP2B6* gene" *The J. of Biological Chemistry," 274(10)*:6043-6046 (1999)	☐
	27	TZAMELI, *et al.* "The Xenobiotic Compound 1,4Bis[2-(3,5-Dichloropyridyloxy)] Benzene is an Agonist Ligand for the Nuclear Receptor CAR" *Molecular and Cellular Biology, 20(9)*:2951-2958 (2000)	☐
	28	WAXMAN, "P450 Gene Induction by Structurally Diverse Xenochemicals: Central Role of Nuclear Receptors CAR, PXR, and PPAR" *Archives of Biochemistry and Biophysics, 369(1)*:11-23 (1999)	☐
	29	WEI, *et al.* "The Nuclear Receptor CAR Mediates Specific Xenobiotic Induction of Drug Metabolism" *Nature, 407*:920-923 (2000)	☐
	30	WILL, *et al.* "Nuclear Orphan Receptors: The Search for Novel Ligangs and Signaling Pathways" *Hormones and Signaling,* Vol. 1, pp. 307-358 (1998)	☐
			☐

WC 9031963 v1

Examiner Signature		Date Considered	8-1-02

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] Applicant is to place a check mark here if English language Translation is attached.

WC 9031963 v1